A class action lawsuit was filed against NeoRx last month, charging the monoclonal antibody developerwith violations of state and federal securities laws. The lawsuitis related to a public stock offering completed by Seattle-basedNeoRx last December.
A class action lawsuit was filed against NeoRx last month, charging the monoclonal antibody developerwith violations of state and federal securities laws. The lawsuitis related to a public stock offering completed by Seattle-basedNeoRx last December.
NeoRx stockholder Murray B. Meld filed the suit May 23 in U.S.District Court in Seattle on behalf of himself and other NeoRxshareholders. The lawsuit charges that NeoRx was aware that amajor shareholder, David Blech, planned to divest his shares inthe company yet did not disclose that information in the offering'sprospectus. Blech sold his NeoRx shares in January and April.
NeoRx denied that it had advance knowledge of Blech's activitiesand will defend itself vigorously, according to chief financialofficer Robert M. Littauer. The lawsuit did not specify a damageclaim.
The impetus for the lawsuit could have come from a sharp declinein NeoRx's stock price after the public offering. NeoRx stockfell from $8.50 a share in January to $3.43 on June 8. The declineappears to be due to the overall softness in biotechnology issues,as well as a decline in stocks held by Blech, who owns an investmentbanking company that came under pressure in April, according toLittauer. NeoRx issued no negative news during that period, hesaid.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
2 Commerce Drive
Cranbury, NJ 08512